澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

IMMUTEP LTD

0.385

0.000

成交量：30.71萬

成交額：11.71萬

市值：5.67億

市盈率：-9.12

高：0.390

開：0.380

低：0.370

收：0.385

52周最高：0.470

52周最低：0.222

股本：14.74億

流通股本：12.28億

量比：0.32

換手率：0.03%

股息：- -

股息率：- -

每股收益(TTM):-0.042

每股收益(LYR):-0.042

淨資產收益率：-36.88%

總資產收益率：-22.66%

市淨率：3.95

市盈率(LYR):-9.12

資料載入中...

總覽公司新聞資訊公告

IMMUTEP LTD發布關於Imp761的積極進展：首個針對自身免疫疾病的Lag-3激動劑抗體的I期研究結果

Immutep與Dr. Reddy's達成戰略合作推廣創新腫瘤藥物Eftilagimod Alfa

IMMUTEP LTD - DR. Reddy's 獲得所有北美、歐洲、日本及大中華區外國家的Eftilagimod Alfa獨家權利

IMMUTEP與DR. Reddy’s達成戰略合作，共同推廣創新腫瘤藥物Eftilagimod Alfa

IMMUTEP LTD - 有資格獲得高達3.495億美元的潛在監管開發和商業里程碑付款

在2025年ESMO大會上，Eftisarc-Neo II期試驗顯示Efti在軟組織肉瘤新輔助治療中的主要終點達成

IMMUTEP LTD宣佈一線非小細胞肺癌Tacti-004（Keynote-F91）III期試驗最新進展

Immutep宣佈與喬治華盛頓大學癌症中心開展研究合作，評估新輔助治療藥物Efti

Immutep宣佈Eftisarc-Neo II期試驗數據獲CTOS 2025大會口頭報告接受該試驗評估Efti在軟組織肉瘤中的新輔助療法

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/IMM.AU/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","market":"AU","secType":"STK","nameCN":"IMMUTEP LTD","latestPrice":0.385,"timestamp":1771981086684,"preClose":0.385,"halted":0,"volume":307103,"delay":0,"changeRate":0,"nameEN":"IMMUTEP LTD","floatShares":1228247159,"shares":1473721306,"eps":-0.042199,"marketStatus":"交易中","change":0,"latestTime":"02-25 11:58:43 AEDT","open":0.38,"high":0.39,"low":0.37,"amount":117114,"amplitude":0.051948,"askPrice":0.39,"askSize":101433,"bidPrice":0.385,"bidSize":72482,"shortable":3,"etf":0,"ttmEps":-0.042199,"tradingStatus":2,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1771995600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.385,"openAndCloseTimeList":[[1771974000000,1771995600000]],"volumeRatio":0.321824,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","floatShares":1228247159,"roa":"-22.66%","roe":"-36.88%","lyrEps":-0.042199,"volumeRatio":0.321824,"shares":1473721306,"dividePrice":0,"high":0.39,"amplitude":0.051948,"preClose":0.385,"low":0.37,"week52Low":0.222,"pbRate":"3.95","psRate":"112.49","week52High":0.47,"institutionHeld":0,"latestPrice":0.385,"committee":-0.166466,"eps":-0.042199,"divideRate":0,"volume":307103,"delay":0,"ttmEps":-0.042199,"open":0.38,"prevYearClose":0.415,"prevWeekClose":0.395,"prevMonthClose":0.395,"prevQuarterClose":0.415,"fiveDayClose":0.385,"twentyDayClose":0.44,"sixtyDayClose":0.285,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMM.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-06-05","symbol":"IMM.AU","defaultRemindTime":1717545600000,"type":"split","dateTimestamp":1717509600000,"forFactor":948148,"toFactor":1000000,"ratio":0.9481480000000001}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMM.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMM.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1132253135","title":"IMMUTEP LTD發布關於Imp761的積極進展：首個針對自身免疫疾病的Lag-3激動劑抗體的I期研究結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1132253135","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132253135?lang=zh_tw&edition=fundamental","pubTime":"2025-12-22 21:02","pubTimestamp":1766408522,"startTime":"0","endTime":"0","summary":"IMMUTEP LTD发布关于Imp761的积极进展：首个针对自身免疫疾病的Lag-3激动剂抗体的I期研究结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"1173503970","title":"Immutep與Dr. Reddy's達成戰略合作 推廣創新腫瘤藥物Eftilagimod Alfa","url":"https://stock-news.laohu8.com/highlight/detail?id=1173503970","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173503970?lang=zh_tw&edition=fundamental","pubTime":"2025-12-08 21:18","pubTimestamp":1765199884,"startTime":"0","endTime":"0","summary":"12月8日 - Immutep Ltd宣布，Immutep与Dr. Reddy’s达成了战略合作协议，共同推广一种创新的肿瘤药物Eftilagimod Alfa。根据协议，Immutep将获得2,000万美元的预付款，以及最高可达3.495亿美元的额外资金。此外，Dr. Reddy's将获得在北美、欧洲、日本及大中华区以外所有国家对Eftilagimod Alfa的独家权利。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"1138437616","title":"IMMUTEP LTD - DR. Reddy's 獲得所有北美、歐洲、日本及大中華區外國家的Eftilagimod Alfa獨家權利","url":"https://stock-news.laohu8.com/highlight/detail?id=1138437616","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138437616?lang=zh_tw&edition=fundamental","pubTime":"2025-12-08 21:09","pubTimestamp":1765199347,"startTime":"0","endTime":"0","summary":"IMMUTEP LTD - DR. Reddy's 获得所有北美、欧洲、日本及大中华区外国家的Eftilagimod Alfa独家权利","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"1156951078","title":"IMMUTEP與DR. Reddy’s達成戰略合作，共同推廣創新腫瘤藥物Eftilagimod Alfa","url":"https://stock-news.laohu8.com/highlight/detail?id=1156951078","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156951078?lang=zh_tw&edition=fundamental","pubTime":"2025-12-08 21:05","pubTimestamp":1765199131,"startTime":"0","endTime":"0","summary":"IMMUTEP与DR. Reddy’s达成战略合作，共同推广创新肿瘤药物Eftilagimod Alfa。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMM.AU"],"gpt_icon":0},{"id":"1192332602","title":"IMMUTEP LTD - 有資格獲得高達3.495億美元的潛在監管開發和商業里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1192332602","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192332602?lang=zh_tw&edition=fundamental","pubTime":"2025-12-08 15:30","pubTimestamp":1765179011,"startTime":"0","endTime":"0","summary":"IMMUTEP LTD - 有资格获得高达3.495亿美元的潜在监管开发和商业里程碑付款","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"1136653615","title":"在2025年ESMO大會上，Eftisarc-Neo II期試驗顯示Efti在軟組織肉瘤新輔助治療中的主要終點達成","url":"https://stock-news.laohu8.com/highlight/detail?id=1136653615","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136653615?lang=zh_tw&edition=fundamental","pubTime":"2025-10-20 20:01","pubTimestamp":1760961701,"startTime":"0","endTime":"0","summary":"在2025年ESMO大会上，Eftisarc-Neo II期试验显示Efti在软组织肉瘤的新辅助治疗中的主要终点达成。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"1137674400","title":"IMMUTEP LTD宣佈一線非小細胞肺癌Tacti-004（Keynote-F91）III期試驗最新進展","url":"https://stock-news.laohu8.com/highlight/detail?id=1137674400","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137674400?lang=zh_tw&edition=fundamental","pubTime":"2025-10-09 20:00","pubTimestamp":1760011230,"startTime":"0","endTime":"0","summary":"IMMUTEP LTD宣布一线非小细胞肺癌Tacti-004（Keynote-F91）III期试验最新进展","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"1124383017","title":"Immutep宣佈與喬治華盛頓大學癌症中心開展研究合作，評估新輔助治療藥物Efti","url":"https://stock-news.laohu8.com/highlight/detail?id=1124383017","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124383017?lang=zh_tw&edition=fundamental","pubTime":"2025-09-22 20:02","pubTimestamp":1758542533,"startTime":"0","endTime":"0","summary":"Immutep宣布与乔治华盛顿大学癌症中心开展研究合作，评估新辅助治疗药物Efti","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMM.AU"],"gpt_icon":0},{"id":"1158451855","title":"Immutep宣佈Eftisarc-Neo II期試驗數據獲CTOS 2025大會口頭報告接受 該試驗評估Efti在軟組織肉瘤中的新輔助療法","url":"https://stock-news.laohu8.com/highlight/detail?id=1158451855","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158451855?lang=zh_tw&edition=fundamental","pubTime":"2025-09-08 20:01","pubTimestamp":1757332877,"startTime":"0","endTime":"0","summary":"Immutep宣布，其Eftisarc-Neo II期临床试验的数据已被CTOS 2025大会接受进行口头报告展示。该试验主要评估新辅助疗法Efti在软组织肉瘤治疗中的效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMM.AU","BK7067"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":9,"code":"91000000","status":"200"}]}}